Detailed description page of ThPDB2

This page displays user query in tabular form.

10846 details
Primary information
ID10846
Therapeutic IDTh1209
Protein NameMethoxy polyethylene glycol-epoetin beta
SequenceNA
Molecular Weight60,000
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeIn CKD patients on peritoneal dialysis with IV administration: 134 ± 65 hours In CKD patients on peritoneal dialysis with SC administration: 139 ± 67 hours
DescriptionMethoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a much longer half-life than erythropoietin. It is produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells and differs from erythropoietin through the integration of an amide bond between either the N- terminal amino group or the ε-amino group of lysine, predominantly Lys52 and Lys45 and methoxy polyethylene glycol butanoic acid. This results in a molecular weight of approximately 60 kDa with the polyethylene glycol-moiety having an approximate molecular weight of 30 kDa. The dosage strength in μg indicates the quantity of the protein moiety of the methoxy polyethylene glycol-epoetin beta molecule without consideration of glycosylation. Methoxy polyethylene glycol-epoetin beta was approved (as Mircera) for use in Europe in July 2007 by the European Commission, in September 2007 by the Swissmedic, and in November 2007 by the U.S. Food and Drug Administration for use in the United States.
Indication/DiseaseFor the treatment of patients with anaemia associated with chronic kidney disease.
PharmacodynamicsFollowing a single-dose of Mircera in CKD patients, the onset of hemoglobin increase (defined as an increase > 0.4 g/dL from baseline) was observed 7 to 15 days following initial dose administration
Mechanism of ActionMircera is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life, in contrast to erythropoietin. A primary growth factor for erythroid development, erythropoietin is produced in the kidney and released into the bloodstream in response to hypoxia. In responding to hypoxia, erythropoietin interacts with erythroid progenitor cells to increase red cell production. Production of endogenous erythropoietin is impaired in patients with CKD and erythropoietin deficiency is the primary cause of their anemia.
ToxicityOverdosage can cause severe hypertension.
MetabolismNot metabolized.
AbsorptionAdministered parenterally (subcutaneous or IV) therefore not absorbed.
~94.74 ml/kg
ClearanceIn CKD patients on peritoneal dialysis : 0.49 ± 0.18 mL/hr/kg
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionLenalidomide, Nandrolone phenpropionate, Thalidomide
TargetErythropoietin receptor
Brand NameMircera
CompanyGenentech, Inc.
Brand DescriptionGenentech, Inc.
Prescribed ForMircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis and patients not on dialysis.
Chemical NameNA
Formulation30 mcg, 50 mcg, 75 mcg, 100 mcg, 120 mcg, 150 mcg, 200 mcg, or 250 mcg in 0.3 mL
Physical Appearance solution for injection
Route of AdministrationIntravenous
Recommended DosageIndividualize dosing and use the lowest dose of Mircera sufficient to reduce the need for RBC transfusions
ContraindicationUncontrolled hypertension; Pure red cell aplasia (PRCA) that begins after treatment with Mircera or other erythropoietin protein drugs; History of serious or severe allergic reactions to Mircera (e.g. anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria).
Side EffectsIncreased Mortality, Myocardial Infarction, Stroke, and Thromboembolism; Increased mortality and/or tumor progression in patients with cancer; Hypertension; Seizures; Pure red cell aplasia; Serious allergic reactions.
Useful Link 1Link
Useful Link 2NA
RemarksNA